Park Avenue Securities LLC Decreases Holdings in Haleon PLC Sponsored ADR $HLN

Park Avenue Securities LLC decreased its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 31.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 114,341 shares of the company’s stock after selling 51,710 shares during the period. Park Avenue Securities LLC’s holdings in Haleon were worth $1,156,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its position in Haleon by 116.7% during the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares during the period. Optiver Holding B.V. purchased a new position in shares of Haleon in the 3rd quarter worth approximately $45,593,000. JPMorgan Chase & Co. increased its position in shares of Haleon by 36.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after purchasing an additional 3,207,986 shares during the last quarter. ABC Arbitrage SA increased its position in shares of Haleon by 159.4% during the 3rd quarter. ABC Arbitrage SA now owns 2,727,350 shares of the company’s stock valued at $24,464,000 after purchasing an additional 1,675,889 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Haleon by 3,548.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,684,968 shares of the company’s stock valued at $17,473,000 after buying an additional 1,638,784 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on HLN shares. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. Morgan Stanley restated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Deutsche Bank Aktiengesellschaft cut shares of Haleon from a “hold” rating to a “sell” rating in a research note on Monday, January 12th. Finally, Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.33.

Haleon Stock Performance

Shares of Haleon stock opened at $9.75 on Thursday. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. The stock’s fifty day moving average is $10.52 and its two-hundred day moving average is $9.88. Haleon PLC Sponsored ADR has a 52 week low of $8.71 and a 52 week high of $11.42. The company has a market capitalization of $43.41 billion, a PE ratio of 24.99 and a beta of 0.18.

Haleon Dividend Announcement

The business also recently declared a dividend, which will be paid on Thursday, May 14th. Stockholders of record on Friday, April 10th will be issued a $0.1307 dividend. The ex-dividend date is Friday, April 10th. This represents a dividend yield of 251.0%. Haleon’s dividend payout ratio is presently 28.21%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.